Any sudden or severe change in symptoms warrants medical attention, particularly if accompanied by intense abdominal pain or persistent vomiting
Current guidelines do not recommend combination therapy with GLP-1 RAs and DPP-4 inhibitors, and the ADA/EASD consensus report specifically recommends discontinuation of DPP-4 inhibitors when initiating GLP-1 RA therapy
It changes from person to person
Maryam Tabatabai Associate Vice President, Clinical Information Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Data Scientist Principal Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior Consultant panel Samantha Decker, PharmD Medical Pharmacy Clinical Pharmacist Natalee Felten, PharmD, BCPS Medical Pharmacy Clinical Pharmacist Andrea Henry, PharmD, MBA, BCPS Drug Information Pharmacist Principal Danny Melson Data Scientist Principal Katie Owen, PharmD, BCOP Clinical Program Pharmacist Principal All brand names are property of their respective owners
[DOI] [PubMed] [Google Scholar] 16.Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L and Holst JJ
